Bolotina, L. V. (2020). Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma. IP Habib O.N.
Style de citation Chicago (17e éd.)Bolotina, L. V. Lenvatinib as the Key Component of First-line Therapy for Patients with Unresectable Hepatocellular Carcinoma. IP Habib O.N, 2020.
Style de citation MLA (8e éd.)Bolotina, L. V. Lenvatinib as the Key Component of First-line Therapy for Patients with Unresectable Hepatocellular Carcinoma. IP Habib O.N, 2020.
Attention : ces citations peuvent ne pas être correctes à 100%.